Aurobindo Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

The USFDA classified the inspection outcome as ?Voluntary Action Indicated? (VAI) and confirmed that the inspection has been closed.

The USFDA had inspected the facility from 8 December to 17 December 2025, following which a Form 483 with five observations was issued at the end of the inspection.

Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.

The company?s consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.

Shares of Aurobindo Pharma shed 0.95% to Rs 1,199.85 on the BSE.

Powered by Capital Market - Live News

Aurobindo Pharma Ltd rose for a fifth straight session today. The stock is quoting at Rs 1312.7, up 2.08% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 1.03% on the day, quoting at 24010.95. The Sensex is at 77280.41, down 1.18%. Aurobindo Pharma Ltd has added around 13.37% in last one month.

Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has added around 4.99% in last one month and is currently quoting at 23253.65, up 1.08% on the day. The volume in the stock stood at 14.65 lakh shares today, compared to the daily average of 17.94 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 1311.6, up 1.56% on the day. Aurobindo Pharma Ltd is up 18.49% in last one year as compared to a 6.86% gain in NIFTY and a 15.08% gain in the Nifty Pharma index.

The PE of the stock is 34.84 based on TTM earnings ending December 25.

Powered by Capital Market - Live News

The product is the generic equivalent of Pomalyst Capsules of BMS Pharmaceuticals Corp. Eugia Pharma Specialities was among the First-to-File (FTF) ANDA applicants. Manufacturing will take place at Eugia Unit-I.

Pomalidomide, a third-generation immunomodulatory drug (IMiD), is used in combination with dexamethasone, and sometimes bortezomib, for relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.

According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately US$ 3.3 billion in the U.S.

Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.

The company?s consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.

Shares of Aurobindo Pharma shed 0.95% to Rs 1,199.85 on the BSE.

Powered by Capital Market - Live News

Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, has launched Pomalidomide Capsules, 1 mg, 2 mg, 3 mg and 4 mg, in the US market. The product is the generic equivalent of Pomalyst? Capsules, 1 mg, 2 mg, 3 mg and 4 mg, of BMS Pharmaceuticals Corp.

Eugia Pharma Specialities was one of the First-to-File (FTF) ANDA applicants for this product. The product will be manufactured at Eugia Unit-I.

According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately US$ 3.3 billion in the U.S.

Pomalidomide is a third-generation immunomodulatory drug (IMiD) used in combination with dexamethasone (and sometimes bortezomib) to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.

Powered by Capital Market - Live News